

February 6, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Sandra Kurla Complex, Sandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai - 400001

Subject: Intimation of Conference Call for Investors/ Analyst for Q3 FY19

Dear Sir/Madam,


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Friday, February 8, 2019 at 4.30 PM 1ST to discuss financial and operating performance for Q3 FY19.

You are requested to take note of the above.


Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra
Company Secretary & Legal Head



Encl: As above

Q3 FY19 Earnings Conference Call Friday, February 8, 2019 at 04:30 pm IST

Gurgaon, February 6, 2019:

Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q3 FY19 results. DLPL will be represented by (Hony) Brig. Dr. Arvind Lal - Chairman and Managing Director, Dr. Om Prakash Manchanda - Whole-time Director and CEO, Mr. Ved Prakash Goel - CFO. We would also have Mr. Bharath U - CEO (India Business) and Mr. Rajat Kalra - Company Secretary & Head of Investor Relations.

The conference call will be initiated with a brief discussion by the management on the Q3 FY19 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	<ul style="list-style-type: none">• 04:30 pm IST on Friday, February 8, 2019
Universal Access	<ul style="list-style-type: none">• Primary – +91 22 6280 1141• Secondary – +91 22 7115 8042
Local Access	<ul style="list-style-type: none">• +91-7045671221 Available all over India.
Conference dial-in International Toll Number	<ul style="list-style-type: none">• USA – 18667462133
	<ul style="list-style-type: none">• UK – 08081011573
	<ul style="list-style-type: none">• Singapore – 8001012045
	<ul style="list-style-type: none">• Hong Kong – 800964448
Replay	<ul style="list-style-type: none">• +91 22 7194 5757 / +91 22 6663 5757• 05609 (passcode)• Valid from February 08, 2019 to February 15, 2019

-ENDS-

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.

As on March 31, 2018 DLPL has 193 clinical labs (including National Reference Lab at Delhi & Kolkata Reference Lab), 2,153 Patient Service Centers (PSCs) and 5,624 Pick-up Points (PUPs). In FY18, DLPL collected and processed approximately 34.7 million samples from approximately 15.2 million patients.

Additional information on Dr. Lal PathLabs Limited:
Corporate Identification No: L74899DL1995PLC065388
Website: <https://www.lalpathlabs.com/>

For further information please contact:

Ved Goel / Rajat Kalra
Dr. Lal PathLabs Limited
Tel: +91 124 301 6500
Fax: +91 124 423 4468
E-mail: ved.goel@lalpathlabs.com
rajat.kalra@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki
CDR India
Tel: +91 22 66451209 / 1221
Fax: +91 22 66451213
Email: siddharth@cdr-india.com
nishid@cdr-india.com